NCT00564928 - A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

March 31, 2010

Study Completion Date

July 31, 2010

Conditions

Prostate CancerProstatic NeoplasmsCancer of the Prostate

Interventions

DRUG

IPI-504

IPI-504 at 400mg/m2, IV, 2 times a week for 2 weeks with 10 days off treatment. Twenty-one (21) day cycle

Trial Locations (10)

MCG Cancer Center, Augusta

Wayne State University, Detroit

University of Chicago Hospitals, Chicago

Parkland Hospital, Dallas

University of Colorado at Denver, Denver

San Bernardino Urological Associates, San Bernardino

Stanford University Medical Center, Stanford

Dana-Farber Cancer Institute, Boston

Massachusetts General Hospital, Boston

Beth Israel Deaconess Medical Center, Boston